A review recently published in Lung Cancer: Targets and Therapy describes patient selection for treatment with bevacizumab, and argues that bevacizumab has a good safety profile in patient subpopulations previously considered ineligible for treatment with the therapy.
Non—small-cell lung cancer (NSCLC) represents approximately 85% of all lung cancers, and more than half of all cases of NSCLC are diagnosed at an advanced stage. Bevacizumab (Avastin and its FDA-approved biosimilar Mvasi), a vascular endothelial growth factor (VEGF) inhibitor is the only antiangiogenic agent approved for first-line treatment of NSCLC, but many patients are considered ineligible to receive the drug. A review recently published in Lung Cancer: Targets and Therapy describes patient selection for treatment with bevacizumab, and argues that bevacizumab has a good safety profile in patient subpopulations previously considered ineligible for treatment with the therapy.
While bevacizumab is generally safe and well tolerated in patients with NSCLC, bleeding in patients treated with the therapy—which may be related to inhibition of the endothelial repair process mediated by VEGF and tumor erosion of vessels—meant that the first randomized clinical trials of bevacizumab in NSCLC excluded patients with squamous histology, significant hemoptysis, tumors invading or abutting major blood vessels, central tumor localization, tumor cavitation, hemorrhage disorders, brain metastases, an Eastern Cooperative Oncology Group grade higher than 1, or an age of 75 or above.
These exclusion criteria, some researchers have suggested, may be too precautionary, and could lead to the inappropriate avoidance of bevacizumab therapy in patients who could benefit from the drug. For example, the authors point out, no statistically significant association has been found between baseline or on-treatment cavitation tumor and severe pulmonary hemorrhage incidence in patients treated with bevacizumab, nor has central tumor location been shown to be a consistent predictive factor for severe pulmonary hemorrhage. While major blood vessel infiltration and bronchial vessel infiltration, encasement, or abutting could predict pulmonary hemorrhage, their valuation is an individual assessment.
Furthermore, several studies, including the phase 2 PASSPORT trial, found that bevacizumab was safe and related to a low incidence of central nervous system hemorrhage in patients with NSCLC and brain metastases.
Retrospective data on bevacizumab in elderly patients with NSCLC yield a conflicting view; a subset analysis of the ECOG 4599 study showed that grade 3 and grade 4 adverse events were significantly more frequent in elderly subjects (87%) than in younger subjects (61%). However, in a retrospective analysis of 304 elderly patients participating in the AVAiL study, improved progression-free survival, without an impact on survival and with no significant toxicities, was observed.
At present, there exist no validated predictive biomarkers of response to treatment with bevacizumab, though recent studies suggest that biomarkers (including circulating levels of VEGF-A isoforms) could correlate with better clinical outcomes in patients with NSCLC treated with antiangiogenesis agents.
The authors conclude that the only absolute contraindications for bevacizumab are squamous histology and a history of clinically significant hemoptysis, and that age, performance status, brain metastases, and anticoagulation therapy do not affect patient eligibility. However, there exists a need for additional translational research into biomarkers predictive of treatment response in order to identify patients who could benefit from treatment with bevacizumab.
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow
May 6th 2025Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.